Jarl Ulf Jungnelius, MD, joins Isofol Medical's Board of Directors

Jarl Ulf Jungnelius, MD, joins Isofol Medical's Board of Directors

Isofol Medical AB today announced that Jarl Ulf Jungnelius, MD, oncologist and Vice President of Oncology, Global Solid Tumors at Celgene, was elected to Isofol Medical's Board of Directors. Ulf is a member of both the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). He is also a clinical advisor to Karolinska Development AB.

"I feel excited to join Isofol, which is a small but highly interesting company with great potential. Isofol Medical strives to improve cancer treatment with folate-based pharmaceuticals and I believe that their lead compound Modufolin® holds great potential to improve the treatment of several different solid tumors" said Ulf Jungnelius.

"Ulf has an impressive track record and extensive experience of clinical development from several leading pharmaceutical companies. He brings highly valuable clinical development competence to Isofol. It is a true pleasure to welcome Ulf onboard as our fifth board member" commented Anders Rabbe, Isofol Medical's CEO.

Ulf's past experience includes leading positions within oncology and clinical development at Celgene, Takeda, Pfizer and Eli Lilly. He has played key roles in the clinical development and regulatory approval process of blockbusters Gemzar® (gemcitabine) and Evista® (raloxifene). Key contributions to the clinical development of pharmaceuticals such as Alimta® (pemetrexed), Revlimid® (lenalidomide) and Vidaza® (azacitidine) are also a part of Ulf's track record. In addition, he has led major Due Diligence processes which have resulted in multibillion dollar acquisitions, including Celgene's acquisitions of Abraxis and Pharmion.

For more information, please contact: Anders Rabbe, CEO, Isofol Medical AB

E-mail: [email protected]

Isofol Medical<http://www.isofolmedical.com> is based on 30 years of medical research which has resulted in the novel folate-based pharmaceutical product Modufolin®. Modufolin® is anticipated to increase the efficacy and reduce the side effects of cytotoxic pharmaceuticals. Isofol works closely with its strategic Swiss R&D partner Merck & Cie, the world's leading manufacturer of reduced folates. In parallel to the drug development, Isofol Medical is performing diagnostic research to personalize and optimize the use of folate-based therapies for cancer treatment.